NO20091864L - Forbindelser for inhibering av mitotisk progresjon - Google Patents

Forbindelser for inhibering av mitotisk progresjon

Info

Publication number
NO20091864L
NO20091864L NO20091864A NO20091864A NO20091864L NO 20091864 L NO20091864 L NO 20091864L NO 20091864 A NO20091864 A NO 20091864A NO 20091864 A NO20091864 A NO 20091864A NO 20091864 L NO20091864 L NO 20091864L
Authority
NO
Norway
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
methods
inhibiting
Prior art date
Application number
NO20091864A
Other languages
English (en)
Other versions
NO343338B1 (no
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091864(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NO20091864L publication Critical patent/NO20091864L/no
Publication of NO343338B1 publication Critical patent/NO343338B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I) og fremgangsmåter for behandling av kreft. Spesielt tilveiebringer oppfinnelsen potente inhibitorer av Aurora A kinase, farmasøytiske sammensetninger omfattende forbindelsene og fremgangsmåter for anvendelse av forbindelsene for behandling av kreft.
NO20091864A 2006-11-16 2009-05-13 Forbindelser for inhibering av mitotisk progresjon og anvendelse derav, samt farmasøytisk sammensetning NO343338B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (2)

Publication Number Publication Date
NO20091864L true NO20091864L (no) 2009-06-15
NO343338B1 NO343338B1 (no) 2019-02-04

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091864A NO343338B1 (no) 2006-11-16 2009-05-13 Forbindelser for inhibering av mitotisk progresjon og anvendelse derav, samt farmasøytisk sammensetning

Country Status (35)

Country Link
US (6) US8026246B2 (no)
EP (4) EP2086981B1 (no)
JP (3) JP5102839B2 (no)
KR (2) KR101342014B1 (no)
CN (2) CN101547924B (no)
AR (1) AR064246A1 (no)
AT (1) ATE556076T1 (no)
AU (1) AU2007322046B2 (no)
BR (1) BRPI0718803B8 (no)
CA (1) CA2669680C (no)
CL (1) CL2007003244A1 (no)
CR (3) CR10782A (no)
CY (1) CY1112828T1 (no)
DK (2) DK2497772T3 (no)
EA (1) EA015779B1 (no)
ES (3) ES2384123T3 (no)
GE (1) GEP20125459B (no)
HK (4) HK1134672A1 (no)
HR (2) HRP20120490T1 (no)
IL (1) IL198690A0 (no)
MA (1) MA30988B1 (no)
MX (3) MX348568B (no)
MY (1) MY153243A (no)
NO (1) NO343338B1 (no)
NZ (3) NZ577042A (no)
PH (1) PH12012502057A1 (no)
PL (2) PL2086981T3 (no)
PT (2) PT2497772E (no)
RS (2) RS52313B (no)
SG (2) SG10201503350TA (no)
SI (2) SI2497772T1 (no)
TW (1) TWI401255B (no)
UA (1) UA94129C2 (no)
WO (1) WO2008063525A1 (no)
ZA (1) ZA200903279B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005243175B2 (en) * 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
EP2373657B1 (en) * 2008-12-05 2016-09-14 Millennium Pharmaceuticals, Inc. 5,7-dihydro-6h-pyrimido[5,4-d][1]benzazepin-6-thiones as plk inhibitors
US20100183601A1 (en) * 2008-12-22 2010-07-22 Millennium Pharmaceuticals, Inc. Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP2013520424A (ja) * 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP2585465B1 (en) * 2010-06-22 2014-11-12 GlaxoSmithKline LLC Benzotriazolodiazepine compounds inhibitors of bromodomains
UY34114A (es) 2011-06-03 2013-01-03 Millennium Pharm Inc Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105209042B (zh) * 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
US20180263979A1 (en) * 2014-12-23 2018-09-20 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CA2997784A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
WO2024006424A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Kras g12c inhibitor for treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
SU1181547A3 (ru) 1979-02-07 1985-09-23 Ф.Хоффманн-Ля Рош Унд Ко,Аг (Фирма) Способ получени пиримидо-2-бензазепинов или их фармакологически совместимых кислотно-аддитивных солей (и его вариант)
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6124281A (en) 1996-03-08 2000-09-26 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
JP2001507349A (ja) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
ID24101A (id) 1997-09-29 2000-07-06 Meiji Seika Kaisha Turunan-turunan triazolobenzazepine trisiklik, proses pembuatan yang sama, dan zat-zat antialergi
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU1651201A (en) 1999-12-06 2001-06-18 Ajinomoto Co., Inc. Amidinophenylpyruvic acid derivative
BR0116411A (pt) 2000-12-21 2003-11-11 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
IL159963A0 (en) 2001-08-09 2004-06-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AU2005243175B2 (en) 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
EP1812424A4 (en) 2004-11-17 2009-07-08 Miikana Therapeutics Inc Kinase Inhibitors
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
KR20080083680A (ko) 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 오로라 키나제의 아자인돌 억제제
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
SG10201503350TA (en) 2015-06-29
DK2497772T3 (en) 2015-01-19
US20080167292A1 (en) 2008-07-10
MX348568B (es) 2017-06-20
HK1217699A1 (zh) 2017-01-20
WO2008063525A1 (en) 2008-05-29
EP2944639B1 (en) 2017-01-04
HRP20150047T1 (en) 2015-03-13
HK1134672A1 (en) 2010-05-07
HK1175778A1 (en) 2013-07-12
CA2669680A1 (en) 2008-05-29
SI2497772T1 (sl) 2015-03-31
HRP20120490T1 (hr) 2012-07-31
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
EP2944639A1 (en) 2015-11-18
CR20140154A (es) 2014-07-23
PH12012502057B1 (en) 2015-09-14
MX343391B (es) 2016-11-04
JP5452811B2 (ja) 2014-03-26
US11958855B2 (en) 2024-04-16
MA30988B1 (fr) 2009-12-01
EP2086981B1 (en) 2012-05-02
US8026246B2 (en) 2011-09-27
CN103483343B (zh) 2016-06-01
AU2007322046A1 (en) 2008-05-29
JP2012006965A (ja) 2012-01-12
BRPI0718803B1 (pt) 2020-11-17
BRPI0718803A2 (pt) 2013-12-03
US20190031662A1 (en) 2019-01-31
IL198690A0 (en) 2010-02-17
ATE556076T1 (de) 2012-05-15
TW200829589A (en) 2008-07-16
CA2669680C (en) 2012-04-10
UA94129C2 (ru) 2011-04-11
CN101547924B (zh) 2013-09-25
EA015779B1 (ru) 2011-12-30
RS53788B1 (en) 2015-06-30
US20110312942A1 (en) 2011-12-22
KR20110113210A (ko) 2011-10-14
KR101342014B1 (ko) 2013-12-19
EP2497772B1 (en) 2014-10-29
EP2086981A1 (en) 2009-08-12
PL2497772T3 (pl) 2015-05-29
US20110312943A1 (en) 2011-12-22
KR101110458B1 (ko) 2012-03-13
EP2497773A1 (en) 2012-09-12
CR20140544A (es) 2015-01-12
JP2010510215A (ja) 2010-04-02
EP2497772A1 (en) 2012-09-12
SG176443A1 (en) 2011-12-29
US10836766B2 (en) 2020-11-17
EA200970486A1 (ru) 2009-10-30
NZ611898A (en) 2015-01-30
JP2014055166A (ja) 2014-03-27
US20210214361A1 (en) 2021-07-15
PH12012502057A1 (en) 2015-09-14
GEP20125459B (en) 2012-03-26
US20150166545A1 (en) 2015-06-18
AR064246A1 (es) 2009-03-25
NZ597252A (en) 2013-06-28
EP2497773B1 (en) 2015-02-25
ES2384123T3 (es) 2012-06-29
NZ577042A (en) 2012-03-30
CL2007003244A1 (es) 2008-04-04
ES2537451T3 (es) 2015-06-08
RS52313B (en) 2012-12-31
MY153243A (en) 2015-01-29
CY1112828T1 (el) 2016-02-10
KR20090091173A (ko) 2009-08-26
DK2086981T3 (da) 2012-08-06
HK1175777A1 (en) 2013-07-12
US9765076B2 (en) 2017-09-19
CN101547924A (zh) 2009-09-30
PL2086981T3 (pl) 2012-09-28
US9988384B2 (en) 2018-06-05
PT2497772E (pt) 2015-02-05
BRPI0718803B8 (pt) 2021-05-25
NO343338B1 (no) 2019-02-04
CR10782A (es) 2009-06-24
TWI401255B (zh) 2013-07-11
SI2086981T1 (sl) 2012-12-31
AU2007322046B2 (en) 2012-04-05
JP5102839B2 (ja) 2012-12-19
ES2528793T3 (es) 2015-02-12
CN103483343A (zh) 2014-01-01
ZA200903279B (en) 2010-07-28

Similar Documents

Publication Publication Date Title
NO20091864L (no) Forbindelser for inhibering av mitotisk progresjon
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
EA200800374A1 (ru) 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
NO20076075L (no) 4-anilino-3-kinolinkarbonitriler for behandling av cancer
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
UA95260C2 (ru) Производное 4-(3-аминопиразол)пиримидина и его применение для лечения злокачественного новообразования
CY1117072T1 (el) Ενωσεις αναστολης της μιτωτικης διαδικασιας